Wednesday, July 21, 2010

Merck To Snag Bankrupt Biotech's Dengue Vaccine Candidate


FiercePharma has the scoop:

. . . .Merck has agreed to purchase bankrupt Hawaii Biotech's dengue fever vaccine unit for an undisclosed sum. It's a critical move for Hawaii, which filed for Chapter 11 bankruptcy protection last year and will deplete a $2 million credit line by the end of this month. . . .

This will add, albeit marginally, to the neglected diseases initiative at Whitehouse Station.

2 comments:

Anonymous said...

Excellent Article!!!!!!
Biotech KPO focuses on the high-end Biotechnology/ Life Sciences services.
· Biotech Strategic Partnership
· Corporate Communications
· Research & Development
· Sales and Marketing
· Human Resource
· Biotechnology/ Life Sciences Consultancy
BioTech KPO www.biotechkpo.com

Research Term Papers said...

I love your blog! You will be in our prayers and thoughts! Nice and informative post on this topic thanks for sharing with us.Thank you!